China Unicom: Dismissed Cao Xingxin as senior vice president

China Unicom (600050) announced on the evening of September 29 that Cao Xingxin, senior vice president and general counsel of the company, is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation by the Central Commission for Discipline Inspection and the State Supervision Commission. In view of the fact that Cao Xingxin no longer meets the qualification requirements for senior management in the Articles of Association, he agreed to dismiss him as senior vice president and general counsel of the company.

Jinling Hotel: A wholly-owned subsidiary acquired 100% equity interest in Jinling Fast Food Company

Jinling Hotel (601007) announced on the evening of September 29 that the company's wholly-owned subsidiary, Food Technology Company, intends to acquire 100% of the equity of Jinling Fast Food Company held by Five Star Industrial Company, a wholly-owned subsidiary of Jinling Hotel Group, in cash, with a transaction price of 9.2 million yuan. This transaction constitutes a related party transaction, but does not constitute a material asset restructuring.

Han Jianheshan: Won the bid for a procurement project of 795 million yuan

Han Jianheshan (603616) announced on the evening of September 29 that the company won the bid for the first bid section of a prestressed steel cylinder concrete pipe procurement project, with an amount of 795 million yuan. The winning project is scheduled to start supplying by April 20, 2025 and end on May 20, 2026. This item accounts for 149.22% of the company's audited operating income in 2023.

Beidahuang: There is a huge gap between the news that the media reported that the company was restored to 127 million and the actual situation

Beidahuang (600598) issued a clarification announcement on the evening of September 29, the company is concerned that there has been a recent news on the Internet about the company and other personnel being restored to the implementation of 127 million, after verification with the relevant person in charge of the company, it is determined that there is a huge gap between the content involved in the above report and the actual situation. This case is a loan dispute between Xinzheng Company and Hanfeng Sustained-Release Fertilizer Co., Ltd., the company, as a former shareholder of Beidahuang Hanfeng and Shangzhi Juyuan Agricultural Development Co., Ltd., was added as the person subject to execution, and jointly and severally liable for repayment within the scope of 4 million yuan without contribution, and the company has filed a lawsuit for enforcement objection. At present, the company has filed an application for retrial of this case with the People's Republic of China High People's Court, and the court has accepted the company's application materials for retrial. As of the disclosure date of this announcement, the company has not received any legal enforcement documents issued by the Intermediate People's Court of Harbin City, Heilongjiang Province.

Chengtou Holdings: Shareholders plan to reduce their holdings of no more than 2% of the company's shares

Chengtou Holdings (600649) announced on the evening of September 29 that Hony Equity Investment Fund Center, a 6.35% shareholder, plans to reduce its holdings of the company's shares by no more than 50,591,500 shares within 3 months after 15 trading days from the date of disclosure of the announcement, through centralized bidding transactions and block transactions, and the reduction ratio does not exceed 2% of the company's total shares.

Fosun Pharma: Oxaliplatin injection, a holding subsidiary, was approved for drug registration

Fosun Pharma (600196) announced on the evening of September 29 that the marketing registration application for oxaliplatin injection (hereinafter referred to as the "new drug") of its holding subsidiary Gasme (Wuhan) Pharmaceutical Co., Ltd. was recently approved by the National Medical Products Administration. The new drug is mainly used in combination with 5-fluorouracil and leucovorin (formyltetrahydro) in the first-line treatment of metastatic colorectal cancer, the adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumor, and the treatment of locally advanced and metastatic hepatocellular carcinoma (HCC) that is not suitable for surgical resection or local therapy.

Guandian Defense: The company's shares may be subject to other risk warnings

Guandian Defense (688287) announced on the evening of September 29 that the company's self-inspection found that as of May 29, 2024, the unreturned amount totaled 159 million yuan, constituting the capital occupation of the listed company by the actual controller and its affiliates, accounting for 15.97% of the company's latest audited net assets attributable to the parent company. If the company cannot solve the above-mentioned capital occupation matters before October 31, 2024 (including October 31), the company's stock trading will be subject to other risk warnings.

Seiko Technology: A wholly-owned subsidiary plans to build a high-performance fiber project of 669 million yuan

Seiko Technology (002006) announced on the evening of September 29 that the company intends to use its own or self-raised funds through its wholly-owned subsidiary Seiko Carbon to invest in the construction of high-performance fiber projects in Shangyu Economic and Technological Development Zone, Hangzhou Bay, Shaoxing City, Zhejiang Province (Seiko Carbon Plant), with an estimated investment of 669 million yuan. The project plans to build two high-performance fiber production lines, with a single-line production capacity of 5,000 tons/year of high-performance fiber, and plans to put into operation in June 2025.

Piano: Temporary suspension of production at the plant of a wholly owned subsidiary

Piano (002853) announced on the evening of September 29 that the company recently temporarily suspended the production line of the factory of Piano Home (Tianjin) Co., Ltd. (hereinafter referred to as "Tianjin subsidiary"), a wholly-owned subsidiary of the company, and transferred the original business orders to the company's Zhongshan Banfu production base, and will resume production at the right time depending on market demand changes.

Jiangnan Chemical: It is planned to list and transfer 55% of the equity of Southern Yongsheng

Jiangnan Chemical (002226) announced on the evening of September 29 that the company intends to transfer 55% of the equity of Southern Yongsheng held by it through the Chongqing Equity Exchange. Zoomlion Asset Appraisal Group Co., Ltd. assessed that the value of all the equity of Southern Yongsheng shareholders was 288 million yuan, and the reserve price of this transfer was 165 million yuan.

Shouxian Valley: Signed a construction contract of 350 million yuan

Shouxian Valley (603896) announced on the evening of September 29 that its wholly-owned subsidiary, Zhejiang Shouxian Valley Digital Intelligence Health Technology Co., Ltd., signed a construction contract with Hangzhou Zhongmin Construction Engineering Co., Ltd., with a total contract price of 350 million yuan (tax included), and the total contract price accounted for about 16.12% of the company's audited net assets in 2023 and about 44.62% of the company's audited operating income in 2023. The signing of the general construction contract aims to promote the construction of the Shouxian Valley Digital Intelligence Center project, which is conducive to improving the company's sustainable profitability and market competitiveness.

Longquan Co., Ltd.: won the bid for the procurement project of 565 million yuan prestressed steel cylinder concrete pipe

Longquan Co., Ltd. (002671) announced on the evening of September 29 that the company received the "Notice of Winning the Bid" issued by a construction and development company issued by the tenderer, and determined that the company was the winning bidder of the "third bid for the procurement of prestressed steel cylinder concrete pipe (PCCP) for a water supply phase II project", with a winning bid price of 565 million yuan (including tax), accounting for about 51% of the company's audited operating income in 2023.

Zhongtian Rocket: Guohua Fund plans to reduce its holdings of no more than 2.5% of the company's shares

Zhongtian Rocket (003009) announced on the evening of September 29 that Guohua Civil-Military Integration Industry Development Fund (Limited Partnership), a 5.53% shareholder, plans to reduce its holdings of the company's shares by centralized bidding or block trading within 3 months from the date of disclosure of the announcement by centralized bidding or block trading no more than 3,884,800 shares (about 2.5% of the company's total share capital).

Guangzhi Technology: Plans to obtain control of Pioneer Electronics Technology Co., Ltd

Guangzhi Technology (300489) announced on the evening of September 29 that the company intends to obtain control of Pioneer Electronic Technology Co., Ltd. by issuing A shares and other means, and raise matching funds. Due to the uncertainty of relevant matters, in order to safeguard the interests of investors and avoid a significant impact on the company's securities trading, according to the relevant regulations of the Shenzhen Stock Exchange, the company's shares have been suspended since the market opened on September 30 upon the company's application.

Hongsheng Huayuan: Chairman Zhao Yongzhi resigned

Hongsheng Huayuan (601096) announced on the evening of September 29 that Zhao Yongzhi applied for resignation as chairman and director of the second board of directors and chairman of the strategy committee of the second board of directors due to work changes, and will no longer hold any other positions in the company after resignation.

Hengrui Pharmaceutical: SHR-1905 injection obtained the drug clinical trial approval notice

Hengrui Pharmaceutical (600276) announced on the evening of September 29 that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" for SHR-1905 injection, and will carry out clinical trials in the near future. SHR-1905 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody that can block the release of inflammatory cytokines, inhibit the conduction of downstream inflammatory signals, and ultimately improve the inflammatory state and control disease progression.

China Merchants Shipping: Aframax tanker new ship delivered

China Merchants Shipping (601872) announced on the evening of September 29 that on September 28, the company received a 115,000-dwt Aframax tanker Kaihe through its wholly-owned single ship company in Dalian Shipbuilding. As of the date of this announcement, the company has 59 100% equity tankers in operation, including 52 VLCCs and 7 Aframax tankers; There are 14 ships in hand, including 6 VLCCs and 8 Aframax, which will be delivered from 2024 to 2028.

SolaX Energy: It plans to invest in the R&D and production of large-scale energy storage systems and smart energy systems

SolaX Energy (688717) announced on the evening of September 29 that the company plans to invest in the construction of a "large-scale energy storage system and smart energy system R&D and production project" in Tonglu Economic Development Zone, Zhejiang Province, and signed an "Investment Agreement" with the Management Committee of Tonglu Economic Development Zone. The total investment of the project shall not be less than 1.05 billion yuan.

Zhonglu Co., Ltd.: Signed a compensation agreement for the reduction and demolition of construction land

Zhonglu Co., Ltd. (600818) announced on the evening of September 29 that the company intends to sign the "Pudong New Area Construction Land Reduction and Demolition Compensation Agreement" with the People's Government of Xuanqiao Town, Pudong New Area, Shanghai and Shanghai Pudong Second Housing Expropriation Service Office Co., Ltd. The company was included in the reduction and demolition compensation plan with a land area of 78,816 square meters, with a total compensation amount of 176 million yuan.

Baili Tianheng: The Phase 1/2a clinical trial application of BL-B01D1 combination drug project for the treatment of advanced solid tumors was approved by the FDA

Baili Tianheng (688506) announced on the evening of September 29 that the company's partner Bristol-Myers Squibb (hereinafter referred to as "BMS", NYSE: BMY) received a notice from the United States Food and Drug Administration (hereinafter referred to as "FDA") that the phase 1/2a clinical trial application for the BL-B01D1 combination drug project for the treatment of advanced solid tumors has been approved by the FDA.

Jiankai Technology: The phase III clinical trial of polyethylene glycol irinotecan for the treatment of small cell lung cancer completed the enrollment of the first subject

Jiankai Technology (688356) announced on the evening of September 29 that the phase III clinical trial of polyethylene glycol irinotecan for injection (drug code: JK1201I) independently developed by Tianjin Jiankai Technology Co., Ltd., a wholly-owned subsidiary, for the treatment of small cell lung cancer, "Phase III clinical study of JK1201I treatment of relapsed or progressive extensive-stage small cell lung cancer" has recently completed the enrollment of the first subject.

Shanghai Yanpu: net profit in the first three quarters is expected to increase by about 68% year-on-year

Shanghai Yanpu (605128) announced on the evening of September 29 that the company expects to achieve a net profit attributable to shareholders of listed companies of about 107 million yuan in the first three quarters of 2024, an increase of about 68% year-on-year. In 2024, the company will start mass production of new projects, the market order volume is sufficient, the company's capacity utilization rate will increase, and the cost will be reduced accordingly. In addition, in 2024, the company's rail transit products, new orders for railway special containers, increased month by month in the third quarter, and the capacity utilization rate increased rapidly, the cost was reduced accordingly, and the product profitability was improved.

Yabao Pharmaceutical: The new indication of SY-009 project obtained the approval notice of phase II clinical trial

Yabao Pharmaceutical (600351) announced on the evening of September 29 that Suzhou Yabao, a holding company, received the "Drug Clinical Trial Approval Notice" for the new indication of SY-009 capsules approved and issued by the State Food and Drug Administration, and approved the application for phase II clinical trials of SY-009 capsules for functional constipation.

People: Chairman Xie Zilong was released from lien

The common people (603883) announced on the evening of September 29 that the company learned on September 29, 2024 that the Hunan Provincial Supervision Commission has lifted the retention measures against Xie Zilong, the actual controller and chairman of the company. After the measures were lifted, Xie Zilong has been able to perform his duties as the company's legal representative and chairman normally. At present, the company's production and operation management is normal.

Hefei Urban Construction: There is uncertainty about whether the purchase of 100% of the equity of Anhui Public Resources Trading Group Co., Ltd. can be successfully implemented

Hefei Urban Construction (002208) issued a change announcement on the evening of September 29, the company intends to issue shares to purchase 100% of the shares of Anhui Public Resources Trading Group Co., Ltd. held by Hefei Xingtai Financial Holdings (Group) Co., Ltd. As of the disclosure date of this announcement, the audit and evaluation of the transaction has not been completed, the specific transaction price of the transaction has not yet been determined, the transaction still needs to be reviewed by the board of directors of the company and the company's general meeting of shareholders to review and approve, and obtain the approval of the State-owned assets supervision and administration department, approved by the Shenzhen Stock Exchange and the China Securities Regulatory Commission to be registered before it can be implemented. There is uncertainty about whether it will be successfully implemented in the end.

Xianda shares: the innovative drug pyrazoquinoxate was approved for registration

Xianda Co., Ltd. (603086) announced on the evening of September 29 that the registration of the innovative drug pyrazoquinate applied for by its wholly-owned subsidiary, Liaoning Xianda Agricultural Science Co., Ltd., has been approved, and pyrazoquinoxate is a new type of herbicide.

Huaxiang shares: plans to set up a joint venture company with 429 million yuan

Huaxiang Co., Ltd. (603112) announced on the evening of September 29 that the company and Huayu Shanghai plan to jointly establish a joint venture company, with a registered capital of 613 million yuan, of which Huayu Shanghai intends to invest 184 million yuan (tentatively priced) with its 100% equity in Shengdeman Shanxi, holding 30% of the equity of the joint venture company; The company intends to contribute 429 million yuan in currency (tentative pricing), hold 70% of the equity of the joint venture company, and implement financial consolidation of the joint venture company. The joint venture will also be committed to the extension of the industrial chain, by deepening the auto parts machining business, enhancing the supply capacity of this business area, so as to achieve the upgrading and optimization of the industrial chain.